IO-202,Venetoclax
Immune-Onc Therapeutics,Roche,Abbvie
['aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'myeloid', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)']
#breaking: our team and investigators will share the first clinical data on io-202 (anti-lilrb4), our first-in-class #myeloid #checkpointinhibitor for the treatment of #aml and #cmml at the #eha2023 congress in frankfurt. learn more: 
Science at Our Core. Patients in Our Hearts.